Ginkgo Bioworks Holdings Inc. [DNA] Revenue clocked in at $197.40 million, up 4.57% YTD: What’s Next?

Related

Ginkgo Bioworks Holdings Inc. [NYSE: DNA] jumped around 0.38 points on 1/3/2022, while shares priced at $8.69 at the close of the session, up 4.57%. The company report on December 31, 2021 that GINKGO BIOWORKS HOLDINGS, INC. F/K/A SOARING EAGLE ACQUISITION CORP. (NYSE:DNA, SRNG) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ginkgo Bioworks Holdings, Inc..

Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than January 18, 2022 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Ginkgo Bioworks Holdings, Inc. f


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


If you purchased or otherwise acquired Ginkgo securities, and/or would like to discuss your legal rights and options, please visit Ginkgo Bioworks Holdings Inc. f/ak/a Soaring Eagle Acquisition Corp Shareholder Class Action Lawsuit or contact Joe Seidman toll free at (877) 779-1414 or seidman@bernlieb.com.

Compared to the average trading volume of 8.83M shares, DNA reached a trading volume of 6456574 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Ginkgo Bioworks Holdings Inc. [DNA]?

Jefferies have made an estimate for Ginkgo Bioworks Holdings Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 29, 2021. While these analysts kept the previous recommendation, Raymond James raised their target price to Outperform. The new note on the price target was released on October 13, 2021, representing the official price target for Ginkgo Bioworks Holdings Inc. stock.

The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc. is set at 0.89, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 76.39. The Price to Book ratio for the last quarter was 7.43, with the Price to Cash per share for the same quarter was set at 1.00.

How has DNA stock performed recently?

Ginkgo Bioworks Holdings Inc. [DNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.69. With this latest performance, DNA shares dropped by -14.97% in over the last four-week period, additionally sinking by -13.19% over the last 6 months .

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 36.80, with the RSI for the last a single of trading hit 33.99, and the three-weeks RSI is set at 39.22 for Ginkgo Bioworks Holdings Inc. [DNA]. The present Moving Average for the last 50 days of trading for this stock 11.87, while it was recorded at 8.80 for the last single week of trading.

Ginkgo Bioworks Holdings Inc. [DNA]: Deeper insight into the fundamentals

Ginkgo Bioworks Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 20.00 and a Current Ratio set at 20.00.

>> 7 Top Picks for the Post-Pandemic Economy <<

Insider trade positions for Ginkgo Bioworks Holdings Inc. [DNA]

There are presently around $6,266 million, or 69.20% of DNA stock, in the hands of institutional investors. The top three institutional holders of DNA stocks are: VIKING GLOBAL INVESTORS LP with ownership of 302,942,974, which is approximately New of the company’s market cap and around 14.10% of the total institutional ownership; GENERAL ATLANTIC, L.P., holding 114,886,852 shares of the stock with an approximate value of $954.71 million in DNA stocks shares; and BAILLIE GIFFORD & CO, currently with $756.23 million in DNA stock with ownership of nearly New of the company’s market capitalization.

98 institutional holders increased their position in Ginkgo Bioworks Holdings Inc. [NYSE:DNA] by around 743,954,649 shares. Additionally, 118 investors decreased positions by around 79,610,452 shares, while 5 investors held positions by with 69,493,723 shares. The mentioned changes placed institutional holdings at 754,071,378 shares, according to the latest SEC report filing. DNA stock had 82 new institutional investments in for a total of 651,766,891 shares, while 97 institutional investors sold positions of 63,767,305 shares during the same period.